Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604014401> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2604014401 abstract "TPS517 Background: Systemic chemotherapy for pancreatic adenocarcinoma improves survival and cancer related symptoms. Most targeted agents combined with gemcitabine have consistently failed to demonstrate clinical benefits. Src is overexpressed in pancreatic cancer and promotes an aggressive cancer phenotype. Dasatinib (D) is an oral multi-tyrosine kinase inhibitor (TKI) affecting tumor proliferation through inhibition of Src, Bcr-Abl, CKit and other pathways. Inhibition of Src is associated with biologic modifications favorably modifying the pancreatic cancer phenotype and has synergy with restoring inherent chemosensitivity. Src inhibition can also increase oxaliplatin activity and modulate Tcell responses. The addition of D to the well-established backbone of FOLFOX represents a multifaceted line of scientific investigation. Methods: This is a multicenter phase II trial to determine activity and toxicity of FOLFOX + D in previously untreated metastatic pancreatic adenocarcinoma. Eligible pts must have at least 1 measurable target lesion by RECIST, ECOG PS 0-2, normal QTc and adequate organ function. Pts received standard cycles of mFOLFOX6 repeated q14d with continuous D (150mg PO daily). Tumor assessments occur q8w. Endpoints included progression-free survival (primary; PFS), objective and biochemical response rates, clinical benefit rate, freedom from metastases, overall survival (OS), toxicity, and quality of life. Exploratory tissue, circulating tumor cell and serum analyses to identify predictors of response are planned, particularly in those demonstrating durable disease control or exceptional response. Sample size was based on a 50% improved median PFS from 4 (historical) to 6 months. NCT01652976. Results: Enrollment continues on this prospective phase II study with 38 of 42 evaluable patients. There are no unexpected toxicities noted thus far. Clinical trial information: NCT01652976. [Table: see text]" @default.
- W2604014401 created "2017-04-07" @default.
- W2604014401 creator A5005675776 @default.
- W2604014401 creator A5008838689 @default.
- W2604014401 creator A5009780509 @default.
- W2604014401 creator A5011787316 @default.
- W2604014401 creator A5012737107 @default.
- W2604014401 creator A5020154592 @default.
- W2604014401 creator A5046488005 @default.
- W2604014401 creator A5052737510 @default.
- W2604014401 creator A5054238636 @default.
- W2604014401 creator A5069022903 @default.
- W2604014401 creator A5069843364 @default.
- W2604014401 creator A5083129512 @default.
- W2604014401 creator A5090416642 @default.
- W2604014401 date "2017-02-01" @default.
- W2604014401 modified "2023-09-26" @default.
- W2604014401 title "5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma." @default.
- W2604014401 doi "https://doi.org/10.1200/jco.2017.35.4_suppl.tps517" @default.
- W2604014401 hasPublicationYear "2017" @default.
- W2604014401 type Work @default.
- W2604014401 sameAs 2604014401 @default.
- W2604014401 citedByCount "0" @default.
- W2604014401 crossrefType "journal-article" @default.
- W2604014401 hasAuthorship W2604014401A5005675776 @default.
- W2604014401 hasAuthorship W2604014401A5008838689 @default.
- W2604014401 hasAuthorship W2604014401A5009780509 @default.
- W2604014401 hasAuthorship W2604014401A5011787316 @default.
- W2604014401 hasAuthorship W2604014401A5012737107 @default.
- W2604014401 hasAuthorship W2604014401A5020154592 @default.
- W2604014401 hasAuthorship W2604014401A5046488005 @default.
- W2604014401 hasAuthorship W2604014401A5052737510 @default.
- W2604014401 hasAuthorship W2604014401A5054238636 @default.
- W2604014401 hasAuthorship W2604014401A5069022903 @default.
- W2604014401 hasAuthorship W2604014401A5069843364 @default.
- W2604014401 hasAuthorship W2604014401A5083129512 @default.
- W2604014401 hasAuthorship W2604014401A5090416642 @default.
- W2604014401 hasConcept C121608353 @default.
- W2604014401 hasConcept C126322002 @default.
- W2604014401 hasConcept C143998085 @default.
- W2604014401 hasConcept C170493617 @default.
- W2604014401 hasConcept C2776694085 @default.
- W2604014401 hasConcept C2778260052 @default.
- W2604014401 hasConcept C2778820342 @default.
- W2604014401 hasConcept C2779536868 @default.
- W2604014401 hasConcept C2780210213 @default.
- W2604014401 hasConcept C2780258809 @default.
- W2604014401 hasConcept C2780962732 @default.
- W2604014401 hasConcept C2781182431 @default.
- W2604014401 hasConcept C42362537 @default.
- W2604014401 hasConcept C502942594 @default.
- W2604014401 hasConcept C526805850 @default.
- W2604014401 hasConcept C71924100 @default.
- W2604014401 hasConceptScore W2604014401C121608353 @default.
- W2604014401 hasConceptScore W2604014401C126322002 @default.
- W2604014401 hasConceptScore W2604014401C143998085 @default.
- W2604014401 hasConceptScore W2604014401C170493617 @default.
- W2604014401 hasConceptScore W2604014401C2776694085 @default.
- W2604014401 hasConceptScore W2604014401C2778260052 @default.
- W2604014401 hasConceptScore W2604014401C2778820342 @default.
- W2604014401 hasConceptScore W2604014401C2779536868 @default.
- W2604014401 hasConceptScore W2604014401C2780210213 @default.
- W2604014401 hasConceptScore W2604014401C2780258809 @default.
- W2604014401 hasConceptScore W2604014401C2780962732 @default.
- W2604014401 hasConceptScore W2604014401C2781182431 @default.
- W2604014401 hasConceptScore W2604014401C42362537 @default.
- W2604014401 hasConceptScore W2604014401C502942594 @default.
- W2604014401 hasConceptScore W2604014401C526805850 @default.
- W2604014401 hasConceptScore W2604014401C71924100 @default.
- W2604014401 hasLocation W26040144011 @default.
- W2604014401 hasOpenAccess W2604014401 @default.
- W2604014401 hasPrimaryLocation W26040144011 @default.
- W2604014401 hasRelatedWork W1597915316 @default.
- W2604014401 hasRelatedWork W2065093995 @default.
- W2604014401 hasRelatedWork W2082842935 @default.
- W2604014401 hasRelatedWork W2138277627 @default.
- W2604014401 hasRelatedWork W2145430926 @default.
- W2604014401 hasRelatedWork W2163866397 @default.
- W2604014401 hasRelatedWork W2248740731 @default.
- W2604014401 hasRelatedWork W2321584397 @default.
- W2604014401 hasRelatedWork W2339356822 @default.
- W2604014401 hasRelatedWork W2591114899 @default.
- W2604014401 hasRelatedWork W2595050331 @default.
- W2604014401 hasRelatedWork W2597840541 @default.
- W2604014401 hasRelatedWork W2598040025 @default.
- W2604014401 hasRelatedWork W2762798619 @default.
- W2604014401 hasRelatedWork W2885142187 @default.
- W2604014401 hasRelatedWork W2997695184 @default.
- W2604014401 hasRelatedWork W3005253567 @default.
- W2604014401 hasRelatedWork W3025271182 @default.
- W2604014401 hasRelatedWork W3168172065 @default.
- W2604014401 hasRelatedWork W3180114390 @default.
- W2604014401 isParatext "false" @default.
- W2604014401 isRetracted "false" @default.
- W2604014401 magId "2604014401" @default.
- W2604014401 workType "article" @default.